Agents and methods for modulating pathogen activity
AssigneesGriffith University, Research Institute At Nationwide Children's Hospital
InventorsMichael P. Jennings, Jennifer L. Edwards, Christopher J. Day, Johnson Mak
Life of this patent
Estimating the term…
Abstract
Ligands of complement receptor 3, including ligands of the I domain of the alpha subunit of this receptor, are useful in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused by such pathogens.
Claims18
A method of treating an infection with a pathogen in a subject infected with the pathogen, wherein the pathogen is a Neisseria species that interacts with a complement receptor 3 (CR3) polypeptide of a CR3 polypeptide-expressing cell, the method comprising administering to the subject an effective amount of a phenylpropionic acid derivative compound of Formula (III):
- wherein:
- R6 is hydrogen, CH3 or CHF2;
- R7 is hydrogen or NH2;
- R8 is hydrogen or OH;
- R9 is hydrogen or C1-4alkyl;
- or a pharmaceutically acceptable salt or solvate thereof, and
- wherein the effective amount of the phenylpropionic acid derivative compound is administered to the subject without administering another antimicrobial agent.
A method of reducing likelihood of developing an infection with a pathogen in a subject not infected with the pathogen but known to be susceptible to the infection and considered likely to develop the infection, or in a subject considered likely to develop a recurrence of a previously treated infection, wherein the pathogen is a Neisseria species that interacts with a complement receptor 3 (CR3) polypeptide of a CR3 polypeptide-expressing cell, the method comprising administering to the subject an effective amount of a phenylpropionic acid derivative compound of Formula (III):
- wherein:
- R6 is hydrogen, CH3 or CHF2;
- R7 is hydrogen or NH2;
- R8 is hydrogen or OH;
- R9 is hydrogen or C1-4alkyl;
- or a pharmaceutically acceptable salt or solvate thereof
- wherein the effective amount of the phenylpropionic acid derivative compound is administered to the subject without administering another antimicrobial agent.
Dependencies are inferred from the claim text.